# A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

> **NCT04492722** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 613 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** AZD5718
- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04492722
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-01
- **Primary completion:** 2022-09-06
- **Final completion:** 2022-09-06
- **Target enrollment:** 613 (ACTUAL)
- **Why stopped:** The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study.
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492722, "A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04492722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*